| Literature DB >> 26348689 |
Ewan Cameron1, Katherine E Battle1, Samir Bhatt1, Daniel J Weiss1, Donal Bisanzio1, Bonnie Mappin1, Ursula Dalrymple1, Simon I Hay2,3,4, David L Smith1, Jamie T Griffin5, Edward A Wenger6, Philip A Eckhoff6, Thomas A Smith7, Melissa A Penny7, Peter W Gething1.
Abstract
In many countries health system data remain too weak to accurately enumerate Plasmodium falciparum malaria cases. In response, cartographic approaches have been developed that link maps of infection prevalence with mathematical relationships to predict the incidence rate of clinical malaria. Microsimulation (or 'agent-based') models represent a powerful new paradigm for defining such relationships; however, differences in model structure and calibration data mean that no consensus yet exists on the optimal form for use in disease-burden estimation. Here we develop a Bayesian statistical procedure combining functional regression-based model emulation with Markov Chain Monte Carlo sampling to calibrate three selected microsimulation models against a purpose-built data set of age-structured prevalence and incidence counts. This allows the generation of ensemble forecasts of the prevalence-incidence relationship stratified by age, transmission seasonality, treatment level and exposure history, from which we predict accelerating returns on investments in large-scale intervention campaigns as transmission and prevalence are progressively reduced.Entities:
Mesh:
Year: 2015 PMID: 26348689 PMCID: PMC4569718 DOI: 10.1038/ncomms9170
Source DB: PubMed Journal: Nat Commun ISSN: 2041-1723 Impact factor: 14.919
Overview of the prevalence–incidence data set used for model calibration.
| Study | Site, Country | Year (s) | Treat. | Threshold | ||
|---|---|---|---|---|---|---|
| Ba | Ndiop, Senegal | 1993 | 0.26 | 0.639 | 1 | >3,600 p μl−1 |
| Bloland | Asembo Bay, Kenya | 1992 | 0.79 | 0.870 | 14 | Age specific |
| Bonnet | Koundou, Cameroon | 1997–1998 | 0.72 | 0.807 | 1 | >1,000 p μl−1 |
| Ebolakouno, Cameroon | 1997–1998 | 0.66 | 0.807 | 1 | >1,000 p μl−1 | |
| Bougouma | Saponé, Burkina Faso | 2007 | 0.67 | 0.770 | 3 | >2,500 p μl−1 |
| Coulibaly | Bandiagara, Mali | 1999 | 0.29 | 0.944 | 7 | Any patent |
| Diallo | Dakar, Senegal | 1996–1997 | 0.014 | 0.495 | 7 | Any patent |
| S. Dakar, | 1994 | 0.003 | 0.495 | 7 | Any patent | |
| Dicko | Donéguébougou, Mali | 1999–2000 | 0.403 | 0.944 | 7 | Any patent |
| Sotuba, Mali | 1999–2000 | 0.086 | 0.944 | 7 | Any patent | |
| Fillol | Niakhar, Senegal | 2003 | 0.22 | 0.820 | 7 | >3,000 p μl−1 |
| Greenwood | Farafenni, The Gambia | 1981–1982 | 0.32 | 0.682 | 30 | Age specific |
| Guinovart | Manhiça, Mozambique | 2003–2005 | 0.20 | 0.820 | Any patent | |
| Henry | Katiola, Côte d'Ivoire | 1997–1998 | 0.91 | 0.686 | 1 | Age specific |
| Korhogo, Côte d'Ivoire | 1997–1998 | 0.88 | 0.686 | 1 | Age specific | |
| Korhogo, Côte d'Ivoire | 1997–1998 | 0.83 | 0.686 | 1 | Age specific | |
| Loha | Chano Mille, Ethiopia | 2009–2011 | 0.044 | 0.812 | 7 | Any patent |
| Lusingu | Mgome, Tanzania | 2001 | 0.91 | 0.850 | 30 | Age specific |
| Ubiri, Tanzania | 2001 | 0.27 | 0.850 | 30 | Age specific | |
| Magamba, Tanzania | 2001 | 0.067 | 0.850 | 30 | Age specific | |
| Molez | Barkedji, Senegal | 1994–1995 | 0.098 | 0.443 | 10 | Age specific |
| Mwangi | Ngerenya, Kenya | 1999–2001 | 0.25 | 0.870 | 7 | >2,500 p μl−1 |
| Chonyi, Kenya | 1999–2001 | 0.41 | 0.870 | 7 | >2,500 p μl−1 | |
| Nebie | Balonghin, Burkina Faso | 2003 | 0.63 | 0.722 | 1 | >5,000 p μl−1 |
| Owusu-Agyei | Kintampo, Ghana | 2004 | 0.72 | 0.922 | 2.33 | >5,000 p μl−1 |
| Rogier | Dielmo, Senegal | 1990 | 0.89 | 0.639 | 1 | Sharp increase |
| Saute | Manhiça, Mozambique | 1996–1999 | 0.26 | 0.384 | 7 | Any patient |
| Schellenberg | Ifakara, Tanzania | 2000–2001 | 0.19 | 0.850 | 7 | Any patient |
| Thompson | Matola, Mozambique | 1992–1995 | 0.38 | 0.526 | 1 | Age specific |
| Trape | Linzolo, Republic of Congo | 1983–1984 | 0.79 | 0.788 | 1 | p/leu. >2 |
| Trape | Dielmo, Senegal | 2007–2008 | 0.20 | 0.950 | 2.33 | p/leu. >3.5 |
| Velema | Pahou, Benin | 1989 | 0.51 | 0.661 | 30 | >1,000 p μl−1 |
ACD, active case detection; PfPR, P. falciparum parasite rate.
*Here τACD denotes the period of ACD in days for each study. Note also that in the Threshold column p μl−1 stands for parasites per microlitre, and p/leu. the ratio of parasites to leucocytes.
†Highlights studies not included in the previous Griffin et al.8 model calibration.
·Symbol denotes the one study here that did not conduct ACD, but was included here for consistency with the previous analysis of Griffin et al.
Figure 1Calibrated posterior predictions of the P. falciparum prevalence–incidence relationship under conditions of low historical treatment and low transmission seasonality from the three microsimulation models comprising our ensemble, stratified by age.
(a,d,g) OpenMalaria; (b,e,h) EMOD DTK; (c,f,i) Griffin IS. In each panel the coloured curve and shaded zones illustrate the (pointwise) median and surrounding 68 and 95% credible intervals for incidence detectable with daily ACD supposing no change to treatment, while the dashed black lines illustrate the median prediction corresponding to a study year intervention increasing the effective treatment rate from 35 to 85% (that is, the ‘observer effect' of ethical study designs).
Figure 2Ensemble model predictions of the P. falciparum prevalence–incidence relationship, stratified by age.
Predictions are given under conditions of low historical treatment and low transmission seasonality (a,d,g), high seasonality (b,e,h) and low seasonality after a 90% decline in EIR over the past 5 years (c,f,i). In each panel the coloured curve and shaded zones illustrate the (pointwise) median and surrounding 68 and 95% credible intervals for incidence detectable with daily ACD. These ensemble predictions represent a weighted average of the calibrated posteriors from each transmission model with weights assigned by the median of subset posteriors algorithm.
Figure 3Ensemble model predictions of changes to clinical incidence resulting from a 90% reduction in EIR over the past 5 years, as a function of starting prevalence.
In each panel the coloured curve and shaded zones illustrate the (pointwise) median and surrounding 68 and 95% credible intervals for the change in incidence detectable with daily ACD. Predictions are given for low (a) and high (b) seasonality settings.